Gland Pharma reported a sequential as well as on-year rise in revenues in Q1, thanks to improving pricing environment in the US, momentum in new product launches and contribution from the newly acquired Cenexi CMO.
Gland Pharma reported a sequential as well as on-year rise in revenues in Q1, thanks to improving pricing environment in the US, momentum in new product launches and contribution from the newly acquired Cenexi CMO. Gland Pharma reported a sequential as well as on-year rise in revenues in Q1, thanks to improving pricing environment in the US, momentum in new product launches and contribution from the newly acquired Cenexi CMO. Moneycontrol Latest News Read More
English 
हिन्दी